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Because tumor cells grow rapidly and randomly, hypoxic regions arise from the lack of oxygen supply in solid tumors. Hypoxic
regions in tumors are known to be resistant to chemotherapy and radiotherapy. Hypoxia-inducible factor-1 (HIF-1) expressed in
hypoxic regions regulates the expression of genes related to tumor growth, angiogenesis, metastasis, and therapy resistance. Thus,
imaging of HIF-1-active regions in tumors is of great interest. HIF-1 activity is regulated by the expression and degradation of
its 𝛼 subunit (HIF-1𝛼), which is degraded in the proteasome under normoxic conditions, but escapes degradation under hypoxic
conditions, allowing it to activate transcription of HIF-1-target genes. Therefore, to image HIF-1-active regions, HIF-1-dependent
reporter systems and injectable probes that are degraded in a manner similar to HIF-1𝛼 have been recently developed and used in
preclinical studies. However, no probe currently used in clinical practice directly assesses HIF-1 activity.Whether the accumulation
of 18F-FDG or 18F-FMISO can be utilized as an index of HIF-1 activity has been investigated in clinical studies. In this review, the
current status of HIF-1 imaging in preclinical and clinical studies is discussed.
1. Introduction
Insufficient blood supply to a rapidly growing solid tumor
leads to hypoxia—oxygen tension that is below physiological
levels. The median value of partial oxygen pressure (pO
2
)
is reportedly 10mmHg in breast cancers but is 65mmHg
in normal breast tissue [1]. Hypoxic regions are not only
critically important in tumor physiology and treatment, but
also strongly associated with malignant progression, thera-
peutic resistance, and poor prognosis [2–4]. In such regions,
the transcription factor hypoxia-inducible factor-1 (HIF-1)
is overexpressed. HIF-1, one of the critical components of
hypoxic responses, is a master transcriptional activator of
various genes related to malignant tumor phenotypes [5–
7]. Therefore, the development of techniques to noninva-
sively detect HIF-1-active hypoxic tumor cells has received
considerable interest. Such techniques will provide useful
information that can be applied to qualitative diagnosis
of tumors and development of therapeutic strategies for
cancer.
2. HIF-1 Biology
HIF-1 is a heterodimeric transcription factor that con-
sists of 𝛼 and 𝛽 subunits (HIF-1𝛼 and HIF-1𝛽, resp.)
[8]. HIF-1𝛽 is a constitutively expressed nuclear pro-
tein; however, HIF-1𝛼 expression is regulated at both the
translational and posttranslational levels. Growth signaling
through receptor tyrosine kinases activates PI3K/Akt/mTOR
and Ras/MEK/ERK signaling pathways and increases HIF-
1𝛼 translation (Figure 1) [9–11]. In contrast, HIF-1𝛼 expres-
sion is maintained at low levels in most normoxic tis-
sues via a posttranslational regulation mechanism—oxygen-
dependent proteasomal degradation. Under normoxic con-
ditions, Pro402 and Pro564 in the HIF-1𝛼 oxygen-dependent
degradation domain (ODD) are hydroxylated by proline
hydroxylases [12–14]. The von Hippel-Lindau tumor sup-
pressor protein (pVHL) specifically recognizes these hydrox-
ylated prolines and interacts with HIF-1𝛼. pVHL forms a
complex with Elongin BC, Cul2, and Rbx1 [15], and this
complex, which acts as a ubiquitin ligase, polyubiquitinates
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Figure 1: Regulatorymechanism of hypoxia-inducible factor (HIF-1) expression. Growth factor stimulation induces HIF-1𝛼 subunit (HIF-1𝛼)
protein synthesis by activating PI3K/Akt/mTOR and Ras/MEK/ERK kinase pathways. Under normoxic conditions, HIF-1𝛼 is hydroxylated
by proline hydroxylases (PHDs), triggering its interaction between von Hippel-Lindau tumor suppressor protein (pVHL), leading to its
polyubiquitination and subsequent proteasomal degradation. In contrast, under hypoxic conditions, HIF-1𝛼 remains stable, enters the
nucleus, and, together withHIF-1𝛽, binds to hypoxia-responsive elements (HREs), upregulating the expression of target genes such as glucose
transporters (GLUTs), vascular endothelial growth factors (VEGFs), and matrix metalloproteinases (MMPs). Ub: ubiquitin.
HIF-1𝛼, leading to its degradation in the 26S proteasome
[16, 17]. However, proline residue hydroxylation does not
occur under hypoxic conditions, allowing HIF-1𝛼 to escape
degradation and move into the nucleus where it asso-
ciates with HIF-1𝛽 and exerts its transcriptional activ-
ity by binding to hypoxia-responsive elements (HREs)
(Figure 1) [18, 19]. Because HIF-1𝛽 is constitutively expressed
in the nucleus, the transcriptional activity of HIF-1 is regu-
lated by HIF-1𝛼 expression and degradation.
HIF-1𝛼 expression is reported to increase dramatically
in conditions where pO
2
is less than 6% (40mmHg) [20].
However, the pO
2
threshold values that lead to HIF-1𝛼 stabi-
lization vary among different organs [21]. Because pulmonary
cells are consistently exposed to relatively high pO
2
, the
values that these cells perceive as abnormal are relatively
high [11]. In contrast, the bone marrow is the only tissue
that expresses HIF-1𝛼 protein under normal physiologi-
cal conditions [22]. Therefore, HIF-1𝛼 is stably present in
“biologically hypoxic regions,” where the tissues and/or cells
themselves sense oxygen deficiency. These regions do not
coincide completely with “physically hypoxic regions,” where
pO
2
is less than 10mmHg. Thus, HIF-1-dependent probes
or reporter systems are required to directly visualize HIF-1-
active hypoxic regions.
3. Monitoring HIF-1 Activity In Vivo by Using
HIF-1-Dependent Reporter Gene Imaging
For the first time, nuclear medical molecular imaging of HIF-
1 activity in vivohas been performedusing aHIF-1-dependent
reporter system. In the field of molecular biology, reporter
systems are commonly used to monitor the expression of
a gene of interest. To directly monitor HIF-1 activity, cell
lines that stably contain a reporter gene suitable for in vivo
imaging downstream of HRE repeats have been established.
When implanted into animals, these cells express the reporter
protein in a HIF-1-dependent manner, and the amount
of reporter protein expression can be measured using a
molecular probe that binds to or is metabolized by these
proteins.
Serganova et al. [23] and Wen et al. [24] performed
positron emission tomography (PET) imaging to detect
HIF-1 activity in tumors, using herpes simplex virus type
1 thymidine kinase (HSV1-TK) as a reporter gene; a PET
reporter of in vivo gene expression has been widely used
[25, 26]. Although endogenous TKs are normally present in
mammalian cells, their substrate specificity differs from that
of HSV-1TK. Because HSV1-TK has broader specificity than
mammalian TKs, a probe that is selectively phosphorylated
by viral TKs can be used to visualize HSV1-TK expression
[27]. Serganova et al. [23] constructed a retroviral vector
bearing the HRE-HSV1-TK reporter gene and transfected
it into C6 glioma cells. The reporter system showed that
dose-dependent patterns in the temporal dynamics of
HIF-1 transcriptional activity were induced by decreased
pO
2
. PET imaging using 2󸀠-[18F]fluoro-2󸀠-deoxy-1𝛽-d-
arabinofuranosyl-5-ethyl-uracil (18F-FEAU), a radioactive
probe selectively metabolized and retained in HSV1-TK-
expressing cells, clearly visualized tumors. The spatial
heterogeneity of HIF-1 transcriptional activity as a function
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of tumor size was shown in a study of reporter xenografts
in mice. With increasing tumor diameter (>3mm), HIF-1
transcriptional activity markedly increased in the tumor core
regions. This marked one of the earliest successes in nuclear
medical molecular imaging for HIF-1 activity in vivo. Since
then, several approaches for noninvasive imaging of HIF-1
activity have been reported, including those using different
combinations of reporter genes and radiolabeled probes
such as sodium-iodide symporter and 99mTc-pertechnetate
[28], glycosylphosphatidylinositol-anchored avidin and
67Ga-DOTA-biotin [29], and HSV1-TK and 9-(4-[18F]fluoro-
3-hydroxymethyl-butyl)guanine (18F-FHBG) [30]. Brader
et al. [31] constructed RH7777Morris hepatoma cells bearing
a triple reporter gene (HRE-HSV1-TK/green fluorescent
protein/firefly luciferase) and prepared an orthotopic liver
tumormodel.They performed 18F-FEAU-PET and luciferase
bioluminescence imaging and succeeded in hypoxia-driven
reporter imaging using both techniques.
HIF-1-dependent reporter systems are also useful
for comparing HIF-1 activity and exogenous markers of
tumor hypoxia. Wen et al. [24] generated rat prostate
adenocarcinoma cells containing HRE-HSV1-TK fused
to enhanced green fluorescent protein as a reporter. PET
imaging was performed using 2󸀠-fluoro-2󸀠-deoxy-1𝛽-d-
arabinofuranosyl-5-[124I]iodouracil (124I-FIAU), and the
distributions of 124I-FIAU and the exogenous hypoxic
cell marker [18F]fluoromisonidazole (18F-FMISO) were
compared. 124I-FIAU PET imaging of hypoxia-induced
reporter gene expression was feasible, and the intratumoral
distributions of 124I-FIAU and 18F-FMISO were similar.
Similar results were obtained for human colorectal HT29
cancer cells bearing the same reporter system [32]. However,
no significant correlation between the 18F-FMISO PET and
HIF-1-dependent reporter readouts has also been reported
[33]. The reasons for the discrepancy between these findings
remain unclear and warrant further investigation. Notably,
these described reporter systems did not include the ODD in
the expressed reporter proteins. The degradation of HIF-1𝛼
is reported to occur within a few minutes under normoxic
conditions [34]. Thus, although reporter protein expression
was regulated by HIF-1, it is necessary to acknowledge that
the reporter proteins may not necessarily reflect real-time
HIF-1 activity once the expression was completed.
4. Molecular Imaging of HIF-1-Active Tumor
Microenvironments by Using Probes with
Oxygen-Dependent Degradation
HIF-1-dependent reporter imaging systems are excellent
tools not only for obtaining spatiotemporal information
regarding HIF-1 expression, but also for evaluating
the effectiveness of hypoxia-targeting therapies in vivo.
However, these systems require exogenous gene transfection
and are difficult to apply to humans. To overcome this
limitation, a number of injectable probes containing ODD
that degrade in an oxygen-dependent manner have been
developed [35–41].
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Figure 2: Principle underlying the imaging of HIF-1-active tumor
microenvironments, using 123I -IPOS. The PTD enables 123I-IPOS
to be delivered to all tissues. In normoxic tissues, oxygen-dependent
POS degradation occurs and 123I-IBB loses its binding partner
and is cleared. In contrast, in hypoxic tissues, 123I-IPOS escapes
degradation and is retained within cells owing to its molecular size.
Thus, 123I-IPOS allows for specific imaging of HIF-1-active hypoxic
microenvironments.
4.1. Chimeric Fusion Protein Probes Containing Oxygen-
Dependent Degradation Domains. To design a probe that
degraded in a manner similar to HIF-1𝛼, Kudo et al. [35]
selected HIF-1𝛼
548–603, the region of ODD that is essential for
oxygen-dependent degradation [42], as the core structure of
the probe. An amino acid sequence that increases cell mem-
brane permeability—the protein transduction domain (PTD)
[43]—was included in the probe to facilitate its transport into
cells. PTD-ODDwas fused tomonomeric streptavidin (SAV),
generating the chimeric protein PTD-ODD-SAV (POS). POS
was then labeled with the radioiodinated biotin derivative
(3-[123I]iodobenzoyl)norbiotinamide (123I-IBB) to produce
123I-IBB-POS (123I-IPOS) [35]. The principle behind the
imaging ofHIF-1-active hypoxicmicroenvironments by using
123I-IPOS is outlined schematically in Figure 2.
125I-IPOS showed more than 2-fold greater accumula-
tion in cells incubated under hypoxic conditions (0.1% O
2
)
than under normoxic conditions (20% O
2
). Size-exclusion
high-performance liquid chromatography (HPLC) analysis
revealed thatmore than 80% of intracellular radioactivity was
derived from intact 125I-IPOS in the hypoxic cells. Reoxy-
genation analysis showed that the intracellular radioactivity
of the reoxygenated group decreased by approximately 40%,
compared to that under hypoxic conditions, and the radioac-
tivity excreted into the medium were mostly attributable
to 125I-IBB and other small molecules [35]. These findings
suggest that 125I-IPOS is stable under hypoxic conditions but
is degraded under normoxic conditions and that 125I-IBB
is excreted from cells. Biodistribution analysis showed that
radioactivity accumulation in tumors 24 h after 125I-IPOS
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administration was 1.4 ± 0.3% of the injected dose per gram
of tissue, and the tumor-to-blood ratio, which serves as an
index of favorable image contrast, was 5.1. Forty-eight hours
after 125I-IPOS administration, radioactivity in the tumor
decreased, but the tumor-to-blood ratio increased [35].
Single-photon emission computed tomography (SPECT)/X-
ray computed tomography imaging with 125I-IPOS clearly
visualized the tumors. Autoradiographic study showed that
the intratumoral distribution of 125I-IPOS is heterogeneous
and corresponds to HIF-1𝛼-positive regions detected using
immunostaining [38]. Moreover, a positive and significant
correlation was observed between 125I-IPOS accumulation
and HIF-1-dependent luciferase bioluminescent signals in
the identical tumor [35]. These findings indicate that 123I-
IPOS is a promising probe for imaging HIF-1-active hypoxic
microenvironments in tumors.
4.2. Rapid Detection of HIF-1-Active Tumor Microenviron-
ments by Using POS: A Pretargeting Approach. Although PET
is used less widely than SPECT in nuclear medical molecular
imaging, it allows for higher sensitivity and resolution, as
well as high-quality quantitative imaging.Thus, PET imaging
of HIF-1-active tumors can provide precise information
for determining appropriate therapeutic strategies and
predicting prognoses of patients. Fluorine-18 is one of the
most widely used radionuclides for PET imaging because
of its ease of production, low positron energy, and adequate
half-life (110min). However, the half-life is too short to obtain
signals 24 h after administration, at which time clear images
can be obtained using 123I-IPOS. Therefore, development
of an imaging procedure that can be used to obtain high-
contrast images during the early period after administration
is required for successful PET imaging using 18F.
A pretargeting approach uses a combination of tumor-
targeting molecules and the prompt clearance of small
radioactive compounds from the blood. One advantage of
this method is that it can provide a high target: nontarget
organ ratios shortly after injection. Therefore, we utilized
a pretargeting approach based on the high-affinity and
specific interaction between SAV and biotin for the PET
imaging of HIF-1-active tumor microenvironments. The
underlying principle of pretargeted imaging of HIF-1-
active hypoxic microenvironments by using POS and
(4-[18F]fluorobenzoyl)norbiotinamide (18F-FBB) is outlined
schematically in Figure 3.
Conjugation of N-succinimidyl-4-[18F]fluorobenzoate
and norbiotinamine yielded 18F-FBB, with a total synthesis
time of 150min, radiochemical yield of 23%, and radiochem-
ical purity of >95%. An in vitro binding assay confirmed that
18F-FBB bound to the SAV moiety of POS. Biodistribution
analysis showed that 18F-FBB was rapidly cleared from the
body without POS pretargeting. The tumor-to-blood and
tumor-to-muscle ratios were <1 at all investigated time
points, indicating that 18F-FBB itself does not show tumor
accumulation. In contrast, 18F-FBB accumulated in tumors
in POS-pretargeted mice. 18F-FBB was able to enter the
tumor cells by passive diffusion owing to its lipophilicity
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Figure 3: Principle underlying the imaging of HIF-1-active tumor
microenvironments, using pretargeted POS and 18F-FBB. The PTD
enables the delivery of POS to all tissues. In normoxic tissues, POS
degrades in a manner similar to HIF-1𝛼. In contrast, in hypoxic
tissues, POS escapes degradation and is retained inside the cells.
After allowing sufficient time for POS to degrade in normal tissues,
18F-FBB is administered. 18F-FBB enters cells by passive diffusion
and binds to the SAV moiety of the POS retained in hypoxic cells;
this does not occur in normoxic tissues.Therefore, pretargeting POS
followed by 18F-FBB administration enables specific imaging ofHIF-
1-active hypoxic microenvironments.
and bind to POS retained in tumor cells. Both tumor-to-
blood and tumor-to-muscle radioactivity ratios increased
over time [37]. Tumor-to-blood ratios comparable to those
at 24 h after 123I-IPOS administration can be obtained within
3 h of 18F-FBB administration by using the pretargeting
method. Pretreatment with excessive d-biotin significantly
inhibited 18F-FBB accumulation in POS-pretargeted tumors.
Size-exclusion HPLC analyses revealed that 80% of intratu-
moral radioactivity is attributable to macromolecules. Taken
together, these findings show that 18F-FBB binds to POS in
vivo, and PET imaging clearly delineated tumors within 3 h
after injecting 18F-FBB into POS-pretargetedmice.Therefore,
the pretargeting approachmakes it possible to reduce the time
taken from probe administration to image acquisition by 8-
fold, allowing imaging to be performed within the half-life
of 18F. In mice with tumors that had been transfected with a
HIF-1-dependent luciferase reporter gene, 18F-FBB accumu-
lation positively correlated with HIF-1-dependent luciferase
bioluminescent signals. The 18F-FBB-distributed areas were
consistent with HIF-1𝛼-positive areas in tumors pretargeted
with POS [37].Thus, these findings demonstrate that 18F-FBB
accumulation in the POS-pretargeted tumors reflects HIF-1-
activity and the pretargeting approach with POS and 18F-FBB
is suitable for rapid imaging of HIF-1-active tumors.
4.3. Peptide Probes Containing Essential Amino Acids for
Oxygen-Dependent Degradation. POS is a 34 kDa protein
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generated in Escherichia coli. Although promising results
for the imaging of HIF-1-active tumor microenvironments
were obtained, as described above, clinical applications
are limited by the possibility of immunogenicity. Pep-
tide probes or small molecules are favorable for clinical
applications because they can be easily synthesized with
high purity and show no immunogenicity. Our research
group succeeded in developing a peptide-based imaging
probe that is degraded in a manner similar to HIF-1𝛼
[41].
Based on the degradation mechanism of HIF-1𝛼, we
selected HIF-1𝛼
547–574 as the basic structure for the oxygen-
sensitive peptide probe. For site-specific radiolabeling, a
glycyl cysteine was introduced into the C-terminal of the
HIF-1𝛼
547–574 scaffold, yielding a peptide named OP30. OP30
was degraded when incubated with HeLa cell lysates but was
unable to penetrate cell membranes. Thus, to increase its
membrane permeability, the nine 𝑁-terminal amino acids
of OP30 were replaced by l-lysine or d-lysine, producing
peptides KOP30 and DKOP30, respectively. As expected,
these modified peptides were also degraded in HeLa cell
lysates and accumulated in the tumor cells. Degradation
was inhibited by the addition of a proteasome inhibitor.
Furthermore, by replacing the proline residues in KOP30
and DKOP30 that are essential for oxygen-dependent degra-
dation with L-alanine, the resulting peptides (mKOP30 and
mDKOP30, resp.,) were not degraded in HeLa cell lysates.
Taken together, these results indicate that the proline residues
and proteasome function are required for the degradation
of KOP30 and DKOP30, similar to HIF-1𝛼. Biodistribution
analysis showed that 125I-DKOP30 had better tumor accumu-
lation and tumor-to-blood ratio than 125I-KOP30. Therefore,
we performed an additional study using 123/125I-DKOP30.
Tumors were visualized clearly by planar imaging using
123I-DKOP30, and autoradiographic studies showed that the
intratumoral distribution of 125I-DKOP30 was consistent
with the HIF-1𝛼-positive areas detected using immunohis-
tochemical staining. Moreover, a positive and significant
correlation was observed between 125I-DKOP30 accumula-
tion and HIF-1-dependent luciferase bioluminescent signals
within the same tumor, whereas no correlation between 125I-
mDKOP30 accumulation and bioluminescent signals was
observed. These findings indicate that 123I-DKOP30 is a
useful peptide probe for imaging HIF-1-active tumors.
Because many peptide probes have already been used in
PET/SPECT imaging in humans [44–46], 123I-DKOP30 has
the most potential probe for imaging HIF-1-active tumors
in clinical settings so far. Using planar imaging, the accu-
mulation of 123I-DKOP30 in tumors was found to be higher
than the background radioactivity in the cervicofacial and
thoracic regions; therefore, it is possible to detect HIF-1
activity in the head and neck, breast, and lung cancers. How-
ever, the high background radioactivity in the abdominal
region would hamper the imaging of HIF-1-active abdom-
inal tumors. To overcome this issue, a probe that demon-
strates greater accumulation in tumors and/or faster clear-
ance from blood and normal abdominal organs should be
developed.
5. Molecular Imaging of HIF-1-Active Tumor
Microenvironments in Clinical Practice
No probes currently used in clinical practice can directly
detect HIF-1 activity. As described in Section 2, pO
2
values
at which HIF-1𝛼 is stable differ between organs. Thus,
in principle, probes targeting physically hypoxic regions
(pO
2
of ≤10mmHg) are not suitable for the detection of HIF-
1 expression or activity because the mechanisms underlying
their hypoxic accumulation are independent of HIF-1 expres-
sion. However, HIF-1𝛼-positive regions reportedly overlap
with pimonidazole-adducted regions in tumors. Although
microscopic observation has shown that unmatched
regions also exist [47, 48], the spatial resolution of nuclear
medical imaging is not sufficiently high to distinguish these
unmatched regions in vivo. Therefore, HIF-1 activity could
potentially be evaluated indirectly by using probes targeting
physically hypoxic regions. In fact, a number of clinical stud-
ies have been performed recently to evaluateHIF-1 expression
in areas of [18F]fluoromisonidazole (18F-FMISO) or 2-deoxy-
2-[18F]fluoro-d-glucose (18F-FDG) accumulation; however,
the obtained results have been discrepant. Furthermore, it
should be noted that neither 18F-FMISO nor 18F-FDG can be
used to evaluate directly the HIF-1 activity, even if the probe
accumulation is correlated with HIF-1 activity.
5.1. 18F-FMISO and Its Derivatives. Sato et al. [49] examined
the relationship between 18F-FMISO PET results and HIF-
1𝛼 expression in patients with oral squamous cell carci-
noma (OSCC). The maximum standardized uptake value
(SUVmax) of 18F-FMISO PET was significantly higher in
HIF-1𝛼-positive patients than in those negative for HIF-
1𝛼. The authors concluded that 18F-FMISO uptake into the
primary site of OSCC indicates the presence of a HIF-
1𝛼-positive hypoxic environment. Kawai et al. [50] evalu-
ated the correlations between 18F-FMISO uptake, HIF-1𝛼
expression, and expression of vascular endothelial growth
factor (VEGF), a HIF-1 target gene, in newly diagnosed
and recurrent malignant gliomas. In contrast to the findings
reported by Sato et al. [49], HIF-1𝛼 expression in the tumors
did not correlate with 18F-FMISO uptake in either newly
diagnosed or recurrent glioma patients. A significant but
weak correlation between VEGF expression and 18F-FMISO
uptake was observed in newly diagnosed glioma patients, but
not in those with recurrent glioma. Hu et al. [51] investigated
the relationship between [18F]fluoroerythronitroimidazole
(18F-FETNIM) uptake and expression of HIF-1𝛼, VEGF, and
glucose transporter 1 (GLUT-1) in nonsmall cell lung cancer.
A positive correlation existed between the tumor-to-muscle
ratio of 18F-FETNIMand the expression of each of theseHIF-
1𝛼 targets.
5.2. 18F-FDG. Sato et al. [49] examined the relationship
between the SUVmax of 18F-FDG and HIF-1𝛼 expression
in OSCC, and no significant correlation was observed. This
finding is in accordance with that reported by Cheng et al.
[52] who found no correlation between 18F-FDG uptake
6 The Scientific World Journal
and HIF-1𝛼 expression in breast cancer patients. Conversely,
Takebayashi et al. [53] investigated the relationship between
the SUVmax of 18F-FDG, HIF-1𝛼 expression, and GLUT-1
expression in gastric cancer patients. The SUVmax was
correlated with HIF-1𝛼 expression, but, interestingly, not
with GLUT-1 expression. In this case, 18F-FDG accumulation
could indicate tissue hypoxia rather than glucose transport
activity in aggressive cancer growths.
6. Conclusion
In this paper, the current status of nuclear medical molecular
imaging strategies for HIF-1-active tumor microenviron-
ments was discussed. At the preclinical level, HIF-1 activ-
ity has been directly evaluated by using HIF-1-dependent
reporter systems and injectable probes that degrade in a
manner similar to HIF-1𝛼. However, these techniques have
not yet been applied clinically. At the clinical level, whether
the accumulation of 18F-FDG or 18F-FMISO can be utilized
as an index of HIF-1 activity has been investigated but results
obtained in these studies varied substantially. To address this
issue, the development of radiolabeled probes that directly
evaluate HIF-1 activity in humans is required.
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